RESUMO
PURPOSE: Induction immunosuppression therapy is used to support optimal outcomes in kidney transplantation. This study was to assess the cost-effectiveness of rabbit antithymocyte globulin (r-ATG) versus ATG-Fresenius (ATG-F) in kidney transplantation in the Chinese setting from the perspective of the health care payer. METHODS: A 2-part survival model was developed, consisting of a short-term part and a long-term part. The short-term part analyzed the first year, using the decision tree, and consisted of the functioning transplant, acute rejection (AR), delayed graft function (DGF), dialysis, and death health states. The long-term part analyzed 2 to 5 years, using Markov model, and consisted of the functioning transplant, chronic dysfunction, recurring primary disease, dialysis, and death health states, with capture of the association between DGF and graft loss. Costs, including drug acquisition and other direct medical costs, were derived from China IQVIA database (formerly known as IMS) hospitaldatabase, chart review, and physician interviews. Clinical outcomes and utility were retrieved from published literature. The model calculated quality-adjusted life-years (QALYs) and total costs per patient. Costs and QALYs were discounted at an annual rate of 3.5%. Univariate sensitivity analysis and probability sensitivity analysis (PSA) were conducted to assess the impact of uncertainty of the variables on the results. FINDINGS: Patients who received r-ATG had more clinical effectiveness than patients who received ATG-F mainly because of less AR, DGF, and dialysis. The incremental QALY was 0.01 over a 1-year time horizon and 0.0496 over a 5-year time horizon. R-ATG and ATG-F drug costs were ¥10,783 and ¥8409, respectively. However, the total treatment costs of the r-ATG arm were lower than the ATG-F arm because of lower costs related to DGF, AR, dialysis, and adverse events. In total, r-ATG saved ¥5423 over the 1-year and ¥7042 over the 5-year time horizon. R-ATG was dominant with lower total direct medical costs and higher QALYs compared with ATG-F. Both univariate sensitivity analysis and PSA found the robustness of the model results. PSA results indicated that r-ATG was cost-effective compared with ATG-F in 86.81% of the simulations, considering <3 times the gross domestic product per capita as the threshold. IMPLICATIONS: From the perspective of the health care payer, r-ATG should be considered as the preferred treatment agent for induction therapy for Chinese patients undergoing kidney transplantation because of its lower overall medical costs and greater QALYs gained compared with ATG-F. The study was limited by lack of long-term efficacy data among the Chinese population and lack of comprehensive real-world higher quality costs data.
Assuntos
Soro Antilinfocitário/administração & dosagem , Imunossupressores/administração & dosagem , Transplante de Rim/métodos , Soro Antilinfocitário/economia , China , Análise Custo-Benefício , Custos de Medicamentos , Humanos , Terapia de Imunossupressão/economia , Imunossupressores/economia , Transplante de Rim/economia , Resultado do TratamentoRESUMO
BACKGROUND: Immunosuppression is required in kidney transplantation to prevent rejection and prolong graft survival. We conducted an economic evaluation to support England's National Institute for Health and Care Excellence in developing updated guidance on the use of immunosuppression, incorporating new immunosuppressive agents, and addressing changes in pricing and the evidence base. METHODS: A discrete-time state transition model was developed to simulate adult kidney transplant patients over their lifetime. A total of 16 different regimens were modelled to assess the cost-effectiveness of basiliximab and rabbit anti-thymocyte globulin (rabbit ATG) as induction agents (with no antibody induction as a comparator) and immediate-release tacrolimus, prolonged-release tacrolimus, mycophenolate mofetil, mycophenolate sodium, sirolimus, everolimus and belatacept as maintenance agents (with ciclosporin and azathioprine as comparators). Graft survival was extrapolated from acute rejection rates, graft function and post-transplant diabetes rates, all estimated at 12 months post-transplantation. National Health Service (NHS) and personal social services costs were included. Cost-effectiveness thresholds of £20 000 and £30 000 per quality-adjusted life year were used. RESULTS: Basiliximab was predicted to be more effective and less costly than rabbit ATG and induction without antibodies. Immediate-release tacrolimus and mycophenolate mofetil were cost-effective as maintenance therapies. Other therapies were either more expensive and less effective or would only be cost-effective if a threshold in excess of £100 000 per quality-adjusted life year were used. CONCLUSIONS: A regimen comprising induction with basiliximab, followed by maintenance therapy with immediate-release tacrolimus and mycophenolate mofetil, is likely to be effective for uncomplicated adult kidney transplant patients and a cost-effective use of NHS resources.
Assuntos
Rejeição de Enxerto/economia , Terapia de Imunossupressão/economia , Imunossupressores/economia , Transplante de Rim/economia , Modelos Econômicos , Adulto , Análise Custo-Benefício , Inglaterra , Rejeição de Enxerto/tratamento farmacológico , Rejeição de Enxerto/etiologia , Sobrevivência de Enxerto , Humanos , Imunossupressores/uso terapêutico , Transplante de Rim/efeitos adversos , Masculino , Pessoa de Meia-Idade , Programas Nacionais de Saúde , Anos de Vida Ajustados por Qualidade de VidaRESUMO
Renal transplantation is the best therapeutic option for end-stage chronic renal disease. Assuming that it is more advisable if performed early, we aimed to show the clinical, social, and economic advantages in 70% of our patients who were dialyzed only for a short period. For this purpose, we retrospectively collected data over 28 years in 142 kidney transplants performed in patients with <6 weeks on dialysis. 66% of our patients were 30-60 years old; 98% of the patients had living donors. At transplantation, 64% of our patients had no public support; however, 64% of them returned to work and got health insurance 2 months later. Full rehabilitation was achieved in all cases, including integration to the family, return to full-time work, school and university, sports, and reproduction. Immunosuppression consisted of 3 drugs, including steroids, cyclosporine, and azathioprine or mycophenolate. The cost in the 1st year, including patient and donor evaluation, surgery, immunosuppression, and follow-up, was $13,300 USD versus $22,320 for hemodialysis. We conclude that preemptive renal transplantation with <6 weeks on dialysis is the best therapeutic option for end-stage renal failure, especially in developing countries such as Bolivia, where until last year, full public support for renal replacement therapy was unavailable.
Assuntos
Falência Renal Crônica/terapia , Transplante de Rim/estatística & dados numéricos , Adulto , Idoso , Azatioprina/economia , Azatioprina/uso terapêutico , Bolívia , Custos e Análise de Custo , Ciclosporina/economia , Ciclosporina/uso terapêutico , Países em Desenvolvimento/economia , Países em Desenvolvimento/estatística & dados numéricos , Feminino , Humanos , Terapia de Imunossupressão/economia , Terapia de Imunossupressão/estatística & dados numéricos , Imunossupressores/economia , Imunossupressores/uso terapêutico , Falência Renal Crônica/economia , Transplante de Rim/economia , Doadores Vivos/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Ácido Micofenólico/economia , Ácido Micofenólico/uso terapêutico , Diálise Renal/economia , Diálise Renal/estatística & dados numéricos , Terapia de Substituição Renal/estatística & dados numéricos , Estudos Retrospectivos , Transplante Homólogo/economia , Transplante Homólogo/estatística & dados numéricosRESUMO
The hypothesis tested in this experiment was that Trichostrongylus colubriformis infection would reduce growth rates of grazing meat-breed lambs; however production loss would be reduced by suppression of the host immune response. The experiment had a 3×2 factorial design using 6-7 month old meat-breed lambs which remained uninfected or infected (IFY) with 2000 or 4000 T. colubriformis L3/week for 12 weeks and were immunosuppressed (SUPY) using methylprednisolone acetate once weekly or remained non-immunosuppressed (SUPN). Immunosuppression increased worm egg counts (WEC) of infected lambs (SUPY 2421 eggs per gram (epg), SUPN 1154 epg on day 84, p<0.05) and T. colubriformis burdens (p<0.05-0.10) and reduced circulating eosinophils (p<0.05 on days 11, 42, 56 and 84) and intestinal total antibody titres (p<0.02). There was a significant (p<0.05) interaction between the main effects of infection and immunosuppression with infection having a larger negative effect on the liveweight of non-immunosuppressed lambs. The immunological response of the host to T. colubriformis infection accounted for 75% of the overall cost of infection (3.1kg) with the majority of this cost occurring during the first 35 days of infection. In contrast, most of the cost associated with the direct effect of infection occurred after day 35. These results confirm in grazing meat-breed lambs that the host's immunological response to T. colubriformis infection is the major component of production loss.
Assuntos
Imunossupressores/uso terapêutico , Metilprednisolona/análogos & derivados , Doenças dos Ovinos/imunologia , Tricostrongilose/veterinária , Trichostrongylus/imunologia , Abomaso/parasitologia , Animais , Anticorpos Anti-Helmínticos/análise , Composição Corporal , Fezes/parasitologia , Feminino , Terapia de Imunossupressão/economia , Imunossupressores/farmacologia , Intestino Delgado/imunologia , Intestino Delgado/parasitologia , Contagem de Leucócitos/veterinária , Masculino , Carne/economia , Metilprednisolona/farmacologia , Metilprednisolona/uso terapêutico , Acetato de Metilprednisolona , Contagem de Ovos de Parasitas/veterinária , Ovinos , Doenças dos Ovinos/economia , Doenças dos Ovinos/parasitologia , Tricostrongilose/economia , Tricostrongilose/imunologia , Trichostrongylus/efeitos dos fármacos , Aumento de PesoRESUMO
Generic immunosuppressive drugs are available in Europe, Canada, and the United States. Between countries, there are large differences in the market penetration of generic drugs in general, and for immunosuppressive drugs in particular. The registration criteria for generic immunosuppressive drugs are often criticized. However, it is unlikely that the criteria for registration of narrow therapeutic index drugs are going to change, and bioequivalence studies, performed in healthy volunteers, will remain the backbone of the registration process. It would be good if the registration authorities would demand that all generic variants of an innovator drug have the same pill appearance to reduce errors and promote drug adherence.To allow for safe substitution, a number of criteria need to be fulfilled. Generic substitution should not be taken out of the hands of the treating physicians. Generic substitution can only be done safely if initiated by the prescriber, and in well-informed and prepared patients. Payers should refrain from forcing pharmacists to dispense generic drugs in patients on maintenance treatment with innovator drug. Instead, together with transplant societies, they should design guidelines on how to implement generic immunosuppressive drugs into clinical practice. Substitutions must be followed by control visits to check if the patient is taking the medication correctly and if drug exposure remains stable. Inadvertent, uncontrolled substitutions from 1 generic to another, initiated outside the scope of the prescriber, must be avoided as they are unsafe. Repetitive subsequent generic substitutions result in minimal additional cost savings and have an inherent risk of medication errors.
Assuntos
Substituição de Medicamentos/tendências , Medicamentos Genéricos/uso terapêutico , Rejeição de Enxerto/prevenção & controle , Sobrevivência de Enxerto/efeitos dos fármacos , Terapia de Imunossupressão/tendências , Imunossupressores/uso terapêutico , Transplante de Órgãos/tendências , Redução de Custos , Análise Custo-Benefício , Custos de Medicamentos , Substituição de Medicamentos/economia , Medicamentos Genéricos/efeitos adversos , Medicamentos Genéricos/economia , Previsões , Rejeição de Enxerto/economia , Rejeição de Enxerto/imunologia , Humanos , Terapia de Imunossupressão/efeitos adversos , Terapia de Imunossupressão/economia , Imunossupressores/efeitos adversos , Imunossupressores/economia , Adesão à Medicação , Erros de Medicação/prevenção & controle , Transplante de Órgãos/efeitos adversos , Transplante de Órgãos/economia , Segurança do Paciente , Padrões de Prática Médica , Fatores de Risco , Fatores de Tempo , Resultado do TratamentoRESUMO
Beta-cell replacement is the only physiologically relevant alternative to insulin injections in patients with type 1 diabetes (T1D). Pancreas and islet transplantation from deceased organ donors can provide a new beta-cell pool to produce insulin, help blood glucose management, and delay secondary diabetes complications. For children and adolescents with T1D, whole pancreas transplantation is not a viable option because of surgical complications, whereas islet transplantation, even if it is procedurally simpler, must still overcome the burden of immunosuppression to become a routine therapy for children in the future.
Assuntos
Diabetes Mellitus Tipo 1/cirurgia , Terapia de Imunossupressão/efeitos adversos , Transplante das Ilhotas Pancreáticas/efeitos adversos , Fatores Etários , Animais , Complicações do Diabetes/prevenção & controle , Diabetes Mellitus Tipo 1/complicações , Diabetes Mellitus Tipo 1/economia , Diabetes Mellitus Tipo 1/imunologia , Custos de Cuidados de Saúde , Humanos , Hiperglicemia/prevenção & controle , Hipoglicemia/prevenção & controle , Terapia de Imunossupressão/economia , Transplante das Ilhotas Pancreáticas/economia , Transplante das Ilhotas Pancreáticas/imunologia , Transplante das Ilhotas Pancreáticas/normas , Transplante de Pâncreas/efeitos adversos , Guias de Prática Clínica como Assunto , Doadores de Tecidos/provisão & distribuição , Transplante Autólogo/efeitos adversos , Transplante Autólogo/economia , Transplante Autólogo/normas , Transplante Heterólogo/efeitos adversos , Transplante Heterólogo/economia , Transplante Heterólogo/normas , Transplante Homólogo/efeitos adversos , Transplante Homólogo/economia , Transplante Homólogo/normas , Estados Unidos , United States Food and Drug AdministrationRESUMO
BACKGROUND: Induction therapy in renal transplantation reduces the incidence of acute rejection (AR) in expanded criteria donation (ECD) and donation after cardiac death (DCD). We compared the efficacy of Thymoglobulin (Sanofi-Aventis, Spain), ATG Fresenius (ATG-Fresenius, Spain), and Simulect (Novartis Farm, Spain) in a calcineurin-free protocol in ECD and DCD renal transplantation by evaluating patient survival, graft survival, and AR at 1 year and overall costs. METHODS: An observational retrospective study was performed using our database of 289 consecutive cadaveric ECD renal transplant recipients (n = 178) and DCD recipients (n = 111) from April 1999 to December 2011. Induction therapy consisted of Simulect, Thymoglobulin, and ATG Fresenius. Calcineurin-inhibitor (CNI)-free maintenance therapy consisted of mycophenolate mofetil or sodium and steroids. RESULTS: There were no differences in the patients' demographic characteristics or patient and graft survival. One-year AR rates were equivalent (ECD: 10%, 19.1%, 17.7% versus DCD: 14.3%, 7.1%, 16.7%). Leukopenia and thrombopenia were significantly more frequent in the ECD group treated with polyclonal induction. The average total cost of transplantation was higher in the ECD group but there were no significant differences in the average total cost between ECD and DCD: 39,970.31 ± 7,732 versus 35,058.34 ± 6,801 (P = NS). CONCLUSION: Our study shows the same efficacy with polyclonal and monoclonal antibody induction and a CNI-free treatment regimen in ECD and DCD renal transplantation with no differences in overall costs at 1 year after transplantation.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Soro Antilinfocitário/uso terapêutico , Rejeição de Enxerto/epidemiologia , Terapia de Imunossupressão/economia , Imunossupressores/uso terapêutico , Transplante de Rim/economia , Proteínas Recombinantes de Fusão/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Anticorpos Monoclonais/economia , Soro Antilinfocitário/economia , Basiliximab , Calcineurina , Inibidores de Calcineurina , Análise Custo-Benefício , Morte , Seleção do Doador , Feminino , Rejeição de Enxerto/economia , Rejeição de Enxerto/prevenção & controle , Sobrevivência de Enxerto , Humanos , Imunossupressores/economia , Incidência , Falência Renal Crônica/economia , Falência Renal Crônica/mortalidade , Falência Renal Crônica/cirurgia , Masculino , Pessoa de Meia-Idade , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapêutico , Proteínas Recombinantes de Fusão/economia , Estudos Retrospectivos , Espanha , Esteroides/uso terapêutico , Resultado do TratamentoRESUMO
OBJECTIVE: Immunosuppression (IS) in islet transplantation (Tx) is a double-edged sword: it prevents immunoreaction but has the potential to impair islet engraftment. The aim of this study was to identify in murine animal models the IS platform with the best balance between these two opposite effects. METHODS: To study the impact of IS on islet engraftment diabetic C57BL/6 mice were transplanted with 350 syngeneic islets through the portal vein and treated once-daily with either rapamycin (RAPA; 0.1-0.5-1 mg/kg ip), tacrolimus (FK506; 0.1-0.5-1 mg/kg ip), mycophenolate mofetil (MMF; 60-120-300 mg/kg oral) or vehicle for 14 days. Islet function was evaluated by measuring not-fasting glycemia and by performing an IVGTT on days 15 and 30 post-Tx. RESULTS: RAPA ≥0.5 mg/Kg, FK506 ≥0.5 mg/Kg, and MMF ≥120 mg/kg had detrimental effects on islet engraftment but not on the function of islets already engrafted in the liver. The effect on engraftment was irreversible and persisted even after IS withdrawal. The lower dose of IS that did not affect engraftment was tested for preventing rejection in the full mismatch allogeneic Tx BALB/c to C57BL/6 model. RAPA and/or FK506 were inefficient in preventing rejection, even when anti-IL2R mAb was added to the IS regimen. On the other hand, MMF alone or in association with FK506 significantly prolonged the time to islet rejection. CONCLUSION: IS showed profound dose-dependent deleterious effects on islet cell engraftment. The MMF/FK506 combination proved the best balance with less toxicity at the time of engraftment and more efficacy in controlling graft rejection.
Assuntos
Diabetes Mellitus Experimental/terapia , Rejeição de Enxerto/prevenção & controle , Tolerância Imunológica/efeitos dos fármacos , Terapia de Imunossupressão/economia , Transplante das Ilhotas Pancreáticas/economia , Ácido Micofenólico/análogos & derivados , Animais , Análise Custo-Benefício , Diabetes Mellitus Experimental/economia , Rejeição de Enxerto/economia , Rejeição de Enxerto/imunologia , Sobrevivência de Enxerto , IMP Desidrogenase/antagonistas & inibidores , Terapia de Imunossupressão/métodos , Imunossupressores/uso terapêutico , Transplante das Ilhotas Pancreáticas/métodos , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Ácido Micofenólico/uso terapêutico , Cuidados Pós-Operatórios/economia , Cuidados Pós-Operatórios/métodosRESUMO
Acquired severe aplastic anaemia (AA) is a serious condition caused by immune-triggered bone marrow failure. For patients not eligible for bone marrow transplantation, treatment of choice is immunosuppression by a combined treatment with antithymocyte globulin (ATG) and cyclosporine. The debate on treatment optimization in AA is focused on conflicting data regarding ATG preparations from horse (h-ATG) versus rabbit (r-ATG), recently favouring h-ATG. H-ATG has been withdrawn from the European market in 2007. Reimbursement for imported preparations from outside Europe is frequently denied in negotiations with statutory health insurance companies. This raises the question of whether h-ATG is cost effective and a sensible investment with regard to healthcare budgets as well as patient health. We modelled the cost effectiveness of r-ATG versus h-ATG based on a recent randomized trial and cost data provided by the hospital pharmacy of Jena University Hospital. We calculated the amount of life years gained and the average incremental costs per life year gained when comparing h-ATG and r-ATG. Our calculations revealed average incremental costs per life year gained of
Assuntos
Anemia Aplástica/economia , Soro Antilinfocitário/economia , Custos de Medicamentos/estatística & dados numéricos , Terapia de Imunossupressão/economia , Modelos Econômicos , Linfócitos T/imunologia , Anemia Aplástica/terapia , Animais , Soro Antilinfocitário/uso terapêutico , Análise Custo-Benefício , Recall de Medicamento , Alemanha , Cavalos/imunologia , Hospitais Universitários/economia , Humanos , Reembolso de Seguro de Saúde , Estimativa de Kaplan-Meier , Expectativa de Vida , Serviço de Farmácia Hospitalar/economia , Coelhos/imunologia , Ensaios Clínicos Controlados Aleatórios como Assunto/economia , Ensaios Clínicos Controlados Aleatórios como Assunto/estatística & dados numéricos , Especificidade da Espécie , Valor da VidaRESUMO
Between August 2006 and August 2009, 34 ethnic Mongolians were the recipients of a kidney transplant at the Central Clinical Hospital in Ulaanbaatar, Mongolia. In 31 of the operations the donor was either a sibling or parent. In 4 recipients the donors were 2 recently deceased accident victims following controlled cardiac arrest and after next of kin permission. All 4 recipients are alive with life-supporting function. Appropriate legislation was passed in 2008. Thirty-one of the 34 recipients (91%) are alive. The 1-year patient and graft survival is 91% and 82%, respectively. In all cases, recipients received 1 dose of Campath 1 preoperatively followed by monotherapy with either Cyclosporin or Tacrolimus. Due to the remote geographical location of some of the recipients, appropriate serum drug levels were difficult to monitor. Azathioprine was therefore added in the last 13 recipients. Except for acute rejection episodes, no patients received steroid therapy. There were 7 diagnosed and treated acute rejections in the 34 recipients (21%). The mean annual cost of the immunosuppressive therapy period compared favorably with neighboring China and with costs in Spain. We conclude that the use of Campath 1 together with a non-steroid maintenance immunosuppressive regimen provides both economical and acceptable graft and patient survival in a developing country.
Assuntos
Transplante de Rim , Adulto , Estudos de Coortes , Custos e Análise de Custo , Feminino , Sobrevivência de Enxerto , Humanos , Terapia de Imunossupressão/economia , Terapia de Imunossupressão/métodos , Transplante de Rim/efeitos adversos , Transplante de Rim/métodos , Transplante de Rim/fisiologia , Doadores Vivos , Masculino , Pessoa de Meia-Idade , Mongólia , Análise de Sobrevida , Doadores de Tecidos , Adulto JovemRESUMO
Kidney transplantation has become an effective treatment for end-stage renal failure. This study analyzed trends in immunosuppressive agent use after renal transplantation at a medical center in southern Taiwan over a 9-year period (2000-2008) seeking to determine whether the trends were consistent with clinical trial outcomes and published guidelines. We identified adult outpatients who had diagnoses of renal transplantation and who had concurrent immunosuppressive drug claims. From 2000-2008, we discovered 39,189 prescriptions related to kidney transplantation. The overall medication consumption showed an increase from 4.9% to 31.9%. Cyclosporine was the main determinant of overall drug costs during these 9 years. The long-term prescribing trend for immunosuppressive use among renal transplantation outpatients showed a clear change during the course of the study. Tacrolimus and sodium mycophenolate/mycophenolate mofetil were used increasingly as combination therapy. However, our survey revealed that management of this transplantation population, especially regarding the use of either calcineurin inhibitor or corticosteroids, was based on potential long-term side effects.
Assuntos
Assistência Ambulatorial/tendências , Rejeição de Enxerto/prevenção & controle , Terapia de Imunossupressão/tendências , Imunossupressores/uso terapêutico , Transplante de Rim , Padrões de Prática Médica/tendências , Adulto , Azatioprina/uso terapêutico , Ciclosporina/uso terapêutico , Custos de Medicamentos/tendências , Quimioterapia Combinada , Uso de Medicamentos/tendências , Rejeição de Enxerto/imunologia , Sobrevivência de Enxerto/efeitos dos fármacos , Humanos , Terapia de Imunossupressão/efeitos adversos , Terapia de Imunossupressão/economia , Imunossupressores/efeitos adversos , Imunossupressores/economia , Transplante de Rim/economia , Transplante de Rim/imunologia , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapêutico , Padrões de Prática Médica/economia , Prednisolona/uso terapêutico , Sirolimo/uso terapêutico , Tacrolimo/uso terapêutico , Taiwan , Fatores de Tempo , Resultado do TratamentoRESUMO
BACKGROUND: Cost of post liver transplant immunosuppression is a major financial burden to patients in developing countries. In India, generic varieties of various immunosuppressants are often used without any definite evidence to their efficacy. This study was aimed at studying the dosage, side effect profile and cost of post-liver transplant immunosuppression using generic products in Indian population following living donor liver transplantation (LDLT). METHODS: Data on dose, cost, and toxicity of immunosuppression were retrieved retrospectively from case records of 59 patients who had undergone LDLT at our center. RESULTS: Adequate immunosuppression was obtained by tacrolimus (Pangraf(®)-Panacea) of 0.04 to 0.05 mg/Kg, and mycophenolate (Mycept(®)-Panacea) of 500 to 1,000 mg; the acute rejection rate was 15% during the first month. Serum tacrolimus levels were 5.4 to 7.3 ng/mL. The cost of immunosuppression varied from Rs. 28,705 in the first month to Rs. 8,820 per month at the end of first year, amounting to an average monthly cost of Rs. 17,250. Approximately 23% and 51% of cost was for mycophenolate and for drug level measurement of tacrolimus, respectively. CONCLUSION: Average cost of immunosuppression after LDLT in India is much lower than that reported elsewhere in the world, since lower drug doses are needed and cheaper generic drugs are available. This can be reduced further by decreasing the frequency of tacrolimus drug level measurement.
Assuntos
Custos de Cuidados de Saúde , Terapia de Imunossupressão/economia , Imunossupressores/economia , Transplante de Fígado/economia , Doadores Vivos , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/efeitos adversos , Índia , Hepatopatias/economia , Hepatopatias/cirurgia , Ácido Micofenólico/administração & dosagem , Ácido Micofenólico/efeitos adversos , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/economia , Estudos Retrospectivos , Tacrolimo/administração & dosagem , Tacrolimo/efeitos adversos , Tacrolimo/economia , Resultado do TratamentoAssuntos
Bioética , Conferências de Consenso como Assunto , Transplante/ética , Humanos , Terapia de Imunossupressão/economia , Terapia de Imunossupressão/normas , América Latina , Doadores Vivos , Obtenção de Tecidos e Órgãos/ética , Obtenção de Tecidos e Órgãos/legislação & jurisprudência , Obtenção de Tecidos e Órgãos/normas , Transplante/normasRESUMO
BACKGROUND: The first generic tacrolimus product gained Food and Drug Administration approval in August 2009. This prospective, observational trial sought to determine the need for dose titrations and measure drug cost savings on conversion to generic tacrolimus. METHODS: Transplant recipients on stable tacrolimus doses were converted from brand to generic tacrolimus on a mg:mg basis. Data were collected at the time of generic conversion (study arm) and at a time point exactly 6 months before conversion (control arm) for all subjects. RESULTS: Seventy conversions from four centers are reported. Subjects were a mean of 70 months after kidney (n=37), liver (n=28), or multiorgan (n=5) transplant. In the study arm, mean tacrolimus doses were 4.4 and 4.5 mg/d and mean tacrolimus trough concentrations were 5.8 and 5.9 ng/mL before and after conversion, respectively. In the control arm, mean tacrolimus doses were 4.6 and 4.6 mg/d and mean tacrolimus trough concentrations were 6.1 and 5.9 ng/mL before and after the control time point, respectively. Dose titrations occurred in five patients (7%) in the control arm and 15 patients (21%) in the study arm (P=0.028). Mean monthly drug costs were $645 for brand, $593 for generic, and $595 for generic after dose titrations. Mean monthly patient copays were $38 for brand and $15 for generic. CONCLUSIONS: These cumulative data show that dose requirements and trough levels are similar between brand and generic tacrolimus and that generic substitution allows for savings. However, postconversion monitoring is prudent as patients may require dose titration.
Assuntos
Terapia de Imunossupressão/economia , Imunossupressores/economia , Imunossupressores/uso terapêutico , Transplante de Órgãos/métodos , Tacrolimo/economia , Tacrolimo/uso terapêutico , Área Sob a Curva , Custos de Medicamentos , Substituição de Medicamentos , Medicamentos Genéricos , Feminino , Humanos , Terapia de Imunossupressão/métodos , Transplante de Rim/métodos , Transplante de Fígado/métodos , Masculino , Estudos Prospectivos , Risco , Resultado do TratamentoAssuntos
Anemia Aplástica/tratamento farmacológico , Terapia de Imunossupressão/economia , Imunossupressores/economia , Imunossupressores/uso terapêutico , Anemia Aplástica/economia , Anemia Aplástica/terapia , Criança , Transplante de Células-Tronco Hematopoéticas/economia , Humanos , Transplante Homólogo/economiaRESUMO
OBJECTIVES: Steroids have had the main role in renal transplant for more than 4 decades. However, chronic use of steroids is associated with many comorbidities, owing to a lack of assessing cost-benefit of steroid avoidance in live-donor renal allotransplants. In this prospective, randomized, controlled study, we aimed to assess the cost-benefit of a steroid-free immunosuppression regimen among Egyptian live-donor renal transplants. MATERIALS AND METHODS: One hundred patients were randomly allocated to receive tacrolimus, mycophenolate mofetil, and steroids for only 3 days (n=50 patients; study group) or tacrolimus, mycophenolate mofetil, and steroids on a maintenance basis (n=50 patients; control group). All patients received basiliximab (Simulect) induction, with median follow-up of 12 months. RESULTS: Both groups showed comparable graft and patient survivals, rejection episodes, and graft functioning. Posttransplant comorbidities were significantly more prevalent in the steroid-maintenance group. Hypertension was detected in 4% of steroid-free group versus 24% in the steroid-maintenance group (P = .0009). Posttransplant diabetes mellitus, serious infections, and hyperlipidemia were significantly more prevalent in the steroid-maintenance group (P < .05). Associated hospitalization costs were 2.2-fold higher in the steroid-maintenance group than they were in the steroid-free group. One year after transplant, the cost of managing posttransplant comorbidities was significantly higher in steroid-maintenance group, despite comparable costs of immunosuppression. CONCLUSIONS: In low, immunologic risk recipients of live-donor renal transplants, using basiliximab induction and maintenance with tacrolimus, mycophenolate mofetil, steroid avoidance was associated with lower first annual total costs despite comparable immunosuppression costs, which was attributed to lower costs of associated morbidities.
Assuntos
Diabetes Mellitus/epidemiologia , Hiperlipidemias/epidemiologia , Hipertensão/epidemiologia , Terapia de Imunossupressão/economia , Imunossupressores/uso terapêutico , Transplante de Rim/imunologia , Doadores Vivos , Esteroides , Adolescente , Adulto , Anticorpos Monoclonais/uso terapêutico , Basiliximab , Comorbidade , Contraindicações , Análise Custo-Benefício , Diabetes Mellitus/economia , Diabetes Mellitus/etiologia , Feminino , Rejeição de Enxerto/epidemiologia , Humanos , Hiperlipidemias/economia , Hiperlipidemias/etiologia , Hipertensão/economia , Hipertensão/etiologia , Terapia de Imunossupressão/métodos , Incidência , Masculino , Pessoa de Meia-Idade , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapêutico , Estudos Prospectivos , Proteínas Recombinantes de Fusão/uso terapêutico , Esteroides/efeitos adversos , Esteroides/uso terapêutico , Tacrolimo/uso terapêutico , Transplante Homólogo , Resultado do Tratamento , Adulto JovemAssuntos
Medicamentos Genéricos/uso terapêutico , Transplante de Células-Tronco Hematopoéticas , Terapia de Imunossupressão , Imunossupressores/uso terapêutico , Custos de Medicamentos , Monitoramento de Medicamentos , Medicamentos Genéricos/efeitos adversos , Medicamentos Genéricos/economia , Medicamentos Genéricos/farmacocinética , Humanos , Terapia de Imunossupressão/economia , Imunossupressores/efeitos adversos , Imunossupressores/economia , Imunossupressores/farmacocinética , Ácido Micofenólico/efeitos adversos , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/economia , Ácido Micofenólico/farmacocinética , Ácido Micofenólico/uso terapêutico , Educação de Pacientes como Assunto , Tacrolimo/efeitos adversos , Tacrolimo/economia , Tacrolimo/farmacocinética , Tacrolimo/uso terapêutico , Equivalência TerapêuticaRESUMO
Of the numerous risks associated with immunotherapy for the prevention of rejection, cost is perhaps the most universal. In the USA and some other countries, the costs of immunosuppression make transplantation unavailable for some medically viable transplant candidates, and for others who receive a transplant, the long-term costs are economically crippling. Minimization and tapering of immunosuppression, use of generics, manipulation of metabolism, infection surveillance instead of prophylaxis, and advantageous routes of administration are some strategies that can be employed to reduce immunotherapy expense. Using these strategies, we describe an immunosuppression regimen for kidney transplantation that might be only a third of the cost of current 'standard' regimens in the USA. Such a regimen might allow some patients who might not otherwise qualify economically to safely receive a kidney transplant. The purpose of creating an alternative, lower-cost immunotherapy regimen is to give patients a choice. Responsible stewardship of scarce donor organs is the primary, and clearly appropriate, limiting factor.
Assuntos
Rejeição de Enxerto/prevenção & controle , Terapia de Imunossupressão/economia , Transplante de Rim/economia , Análise Custo-Benefício , Rejeição de Enxerto/economia , Humanos , Imunossupressores/economia , Imunossupressores/uso terapêutico , Imunoterapia/economia , Imunoterapia/métodos , Transplante de Rim/efeitos adversos , Doadores de Tecidos , Estados UnidosRESUMO
AIMS: To describe the dynamic of a model of public government partnership for dialysis and transplantation in developing countries. MATERIALS: A model was established on the philosophy of public-government partnership to provide an integrated dialysis and transplant service "Free with dignity" with lifelong follow-up care and medications. The government provided 50% of funds and the public was motivated to donate the rest. This included affluent individuals, corporations, business houses and the general public. RESULTS: This model has been sustained for the last two decades. In 2008, 655,000 patients were treated at SIUT. Over 600 patients are dialyzed each day with a total of 165,411 dialysis sessions/year. Thus far 2,249 transplants have been performed, 431 in 2008. One- and 5-year graft survival rates were 92% and 85%, respectively. The laboratory performed 4.1 million tests and radiological investigations numbered 164,217. Over $ 6 million were spent on medications. Free services offered by the model have motivated the government to increase its funding from $ 2.1 million in 1998 to $ 10 million in 2008 and the public has matched these figures with total donations exceeding $ 20 million. CONCLUSIONS: For transplantation to be successful in developing countries, it has to be made available to the common people who constitute 90% of the population. Our model of public-government partnership has made dialysis and transplantation available to the disenfranchised with lifelong follow-up and medications. Transplantation has become relevant to them, resulting in societal acceptance of transplantation as a preferred mode of therapy. This has motivated society to support both living related and deceased donor programs.